Healthcare Realty's Turnaround Is Working-But at 21, the Easy Money May Be Gone

Healthcare Realty's latest quarter shifted the story

This turned from a "broken REIT" debate to a "can it re-rate?" debate the moment management lifted guidance while the stock was still near the bottom of its recovery. In the latest quarter, Healthcare Realty posted NAREIT FFO of $0.35, normalized FFO of $0.41, and then pushed its 2026 outlook higher. That matters because markets stop rewarding "less bad" results once the business starts looking operationally credible.

The operating metrics improved across the board

The company also reported same store cash NOI growth of +6.9%, tenant retention of 93.5%, and +4.2% cash leasing spreads. Management raised both its 2026 normalized FFO guidance and its same-store cash NOI growth guidance. For a business the Street had marked down as structurally impaired, those are the kind of numbers that make investors ask whether this is a durable turnaround rather than a temporary squeeze.

Bulls and bears now have different reference points

Bulls see the early stage of a multiple shift. The shares closed at $21.01 and remain above the 52-week average price of $18.36. Bears argue the easy money is gone: the stock is now near its recent range high, so investors are no longer buying panic prices. That is the right way to frame it. This is no longer a bargain-bin story; it is a credibility test.

Leasing activity and capital discipline are the real improvements

The key change is not just that demand returned, but that it showed up in the quality of the leases. Healthcare Realty executed 286,000 square feet of new lease executions during the first quarter, and total lease executions covered 2.0 million square feet across same-store properties and redevelopment projects. That is the mechanism bulls care about: more leases, including fresh renewals and new business, support the next leg of rent growth.

Why lease volume matters beyond one quarter

Lease activity matters because it changes the shape of income. Renewals lock in retention with existing tenants, while new leases add fresh rent bases and reduce reliance on any single renewal negotiation. The presence of new lease executions matters as much as the total volume because it shows demand is broad enough to reduce distortion from weak renewals. For a REIT trying to rebuild credibility, that distinction matters.

Capital deployment is looking more selective

The first-quarter results also showed more selective capital use. The company completed approximately $125 million of transactions, including the first new acquisition in the KKR joint venture since formation for $89 million and dispositions of $33 million. It also repurchased 5.7 million shares of common stock at an average price of $17.38 per share for a total of $100 million. Taken together, that looks less like defensive damage control and more like a business trying to strengthen asset quality while still returning capital.

Healthcare Realty is still cheap relative to its guided earnings power

At this price, the right question is not whether Healthcare Realty looks cheap on paper. It is whether the stock is cheap enough to own here. The paper case is still intact: management has raised its 2026 Normalized FFO guidance range of $1.59 to $1.65 per share, and even after the recent run, the shares still closed at $21.01. That means investors are paying for a credible earnings path, not discounting a broken business.

Cheap on paper is not the same as cheap enough to own

That is the proving-ground thesis. The all-time high is 21.87, and the 52-week high is 22.04, so the stock is no longer trading like a distressed REIT. It is trading like a business that has regained some credibility. If full-year results walk toward the top of management's guided range, a higher share price can be justified. If execution slips, there is less excuse value to cushion a repricing.

What would keep the turnaround thesis intact

The next update matters less for heroic upside surprises and more for consistency. The bullish case holds if operating gains in NOI, retention, and leasing activity continue to support the guided 2026 range. The bearish case strengthens if those metrics cool or if management backs away from the updated outlook.

Insider alignment and dividend details matter more now

Operating proof is no longer the edge. At $21.01, with the shares only just below their all-time high of 21.87, the next edge sits in the filings. Watch the company's Forms 3, 4 & 5 for real insider buying or selling, not just press-release optimism. If executives are adding stock or holding firm while the shares trade near peaks, that is a positive signal on alignment. If they are unloading shares, the market is likely to treat that more seriously than guidance commentary.

The same discipline applies to pay and payout. The proxy statement is the place to check whether ownership and compensation are tied closely enough to long-term execution. And the dividend needs a closer look too: the 2025 dividend tax treatment showed a nondividend distribution component, which means investors should not read the yield at face value.